ABT-751 hydrochloride
SIGMA/SML0131 - ≥98% (HPLC)
Synonym: N-
CAS Number: 141450-48-8
Empirical Formula (Hill Notation): C18H17N3O4S · HCl
Molecular Weight: 407.87
MDL Number: MFCD19440802
Linear Formula: C18H17N3O4S · HCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | pink to purple |
| form | powder |
| InChI | 1S/C18H17N3O4S.ClH/c1-25- |
| InChI key | KWQWWUXRGIIBAS-UHFFFAOYSA |
| originator | Abbott |
| Quality Level | 100 ![]() |
| SMILES string | Cl.COc1ccc(cc1)S(=O)(=O)N |
| solubility | DMSO: ≥15 mg/mL |
| storage condition | desiccated |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | ABT-751 is an orally bioavailable vascular disrupting agent (VDA) with a broad spectrum of antitumor activity. It binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules. |
| Biochem/physiol Actions: | ABT-751, a sulfonamide antimitotic agent, is under clinical trials to treat patients with various malignancies including refractory hematologic malignancies, non-small cell lung cancer (NSCLC), and colon cancer. |
| Biochem/physiol Actions: | Orally bioavailable vascular disrupting agent (VDA) that binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules; broad spectrum of antitumor activity. |
| Features and Benefits: | This compound was developed by Abbott . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H315 - H319 - H335 |
| Precautionary statements | P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


